SinoMab BioScience Ltd - ESG Rating & Company Profile powered by AI
Other companies in the rating peer group for SinoMab BioScience Ltd are shownin the table. Detailed Sustainability analysis of SinoMab BioScience Ltd are reached by logging in. This Disclosure score covers seventeen UN SDGs including: 'Gender Equality', 'Industry, Innovation & Infrastructure' and 'Life below Water'.
SinoMab BioScience Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.5; made up of an environmental score of 1.6, social score of 3.2 and governance score of 2.7.
2.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1954 | Vaxcell Bio Therapeutics | 2.6 | Medium |
| 1954 | Zhejiang Starry Pharmaceutical Co Ltd | 2.6 | Medium |
| 1976 | SinoMab BioScience Ltd | 2.5 | Medium |
| 1976 | Chemon Inc | 2.5 | Medium |
| 1976 | Chengdu Kanghong Pharmaceutical Group Co Ltd | 2.5 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does SinoMab BioScience Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes SinoMab BioScience Ltd report the average age of the workforce?
Sign up for free to unlockDoes SinoMab BioScience Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes SinoMab BioScience Ltd offer flexible work?
Sign up for free to unlockDoes SinoMab BioScience Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes SinoMab BioScience Ltd conduct supply chain audits?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes SinoMab BioScience Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose water use targets?
Sign up for free to unlockDoes SinoMab BioScience Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid SinoMab BioScience Ltd have a product recall in the last two years?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes SinoMab BioScience Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas SinoMab BioScience Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose parental leave metrics?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes SinoMab BioScience Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes SinoMab BioScience Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs SinoMab BioScience Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose its waste policy?
Sign up for free to unlockDoes SinoMab BioScience Ltd report according to TCFD requirements?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose energy use targets?
Sign up for free to unlockDoes SinoMab BioScience Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes SinoMab BioScience Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for SinoMab BioScience Ltd
These potential risks are based on the size, segment and geographies of the company.
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.